|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Markman M and Bookman MA: Second-line
treatment of ovarian cancer. Oncologist. 5:26–35. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Assis J, Pereira C, Nogueira A, Pereira D,
Carreira R and Medeiros R: Genetic variants as ovarian cancer
first-line treatment hallmarks: A systematic review and
meta-analysis. Cancer Treat Rev. 61:35–52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marchetti C, De Felice F, Romito A,
Iacobelli V, Sassu CM, Corrado G, Ricci C, Scambia G and Fagotti A:
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms
and emerging treatments. Semin Cancer Biol. 77:144–166. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khan MA, Vikramdeo KS, Sudan SK, Singh S,
Wilhite A, Dasgupta S, Rocconi RP and Singh AP: Platinum-resistant
ovarian cancer: From drug resistance mechanisms to liquid
biopsy-based biomarkers for disease management. Semin Cancer Biol.
77:99–109. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lheureux S, Gourley C, Vergote I and Oza
AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kurnit KC, Fleming GF and Lengyel E:
Updates and new options in advanced epithelial ovarian cancer
treatment. Obstet Gynecol. 137:108–121. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Wei H, Liu X, Wang N, Qi Y, Zhang
Y and Zhang S: Downregulation of phosphoglycerate dehydrogenase
inhibits proliferation and enhances cisplatin sensitivity in
cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3.
Cancer Biol Ther. 16:541–548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Binju M, Amaya-Padilla MA, Wan G,
Gunosewoyo H, Suryo Rahmanto Y and Yu Y: Therapeutic inducers of
apoptosis in ovarian cancer. Cancers (Basel). 11:17862019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kartalou M and Essigmann JM: Mechanisms of
resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wernyj RP and Morin PJ: Molecular
mechanisms of platinum resistance: Still searching for the
Achilles' heel. Drug Resist Updat. 7:227–232. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cancer Genome Altas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meyer N and Penn LZ: Reflecting on 25
years with MYC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neri F, Zippo A, Krepelova A, Cherubini A,
Rocchigiani M and Oliviero S: Myc regulates the transcription of
the PRC2 gene to control the expression of developmental genes in
embryonic stem cells. Mol Cell Biol. 32:840–851. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zajac-Kaye M: Myc oncogene: A key
component in cell cycle regulation and its implication for lung
cancer. Lung Cancer. 34 (Suppl 2):S43–S46. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boxer RB, Jang JW, Sintasath L and Chodosh
LA: Lack of sustained regression of c-MYC-induced mammary
adenocarcinomas following brief or prolonged MYC inactivation.
Cancer Cell. 6:577–586. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bild AH, Yao G, Chang JT, Wang Q, Potti A,
Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al:
Oncogenic pathway signatures in human cancers as a guide to
targeted therapies. Nature. 439:353–357. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mo H, Vita M, Crespin M and Henriksson M:
Myc overexpression enhances apoptosis induced by small molecules.
Cell Cycle. 5:2191–2194. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McMahon SB: MYC and the control of
apoptosis. Cold Spring Harb Perspect Med. 4:a0144072014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Koach J, Holien JK, Massudi H, Carter DR,
Ciampa OC, Herath M, Lim T, Seneviratne JA, Milazzo G, Murray JE,
et al: Drugging MYCN oncogenic signaling through the MYCN-PA2G4
binding interface. Cancer Res. 79:5652–5667. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Beltran H: The N-myc oncogene: Maximizing
its targets, regulation, and therapeutic potential. Mol Cancer Res.
12:815–822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jung M, Russell AJ, Liu B, George J, Liu
PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, London WB, et al: A
Myc activity signature predicts poor clinical outcomes in
Myc-associated cancers. Cancer Res. 77:971–981. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakagawara A, Li Y, Izumi H, Muramori K,
Inada H and Nishi M: Neuroblastoma. Jpn J Clin Oncol. 48:214–241.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mizukami Y, Nonomura A, Takizawa T,
Noguchi M, Michigishi T, Nakamura S and Ishizaki T: N-myc protein
expression in human breast carcinoma: Prognostic implications.
Anticancer Res. 15:2899–2905. 1995.PubMed/NCBI
|
|
26
|
Huang X, Qi L, Lu W, Li Z, Li W and Li F:
MYCN contributes to the sensitization of acute myelogenous leukemia
cells to cisplatin by targeting SRY-box transcription factor 4.
Bioengineered. 2021. View Article : Google Scholar
|
|
27
|
Veskimäe K, Scaravilli M, Niininen W,
Karvonen H, Jaatinen S, Nykter M, Visakorpi T, Mäenpää J, Ungureanu
D and Staff S: Expression analysis of platinum sensitive and
resistant epithelial ovarian cancer patient samples reveals new
candidates for targeted therapies. Transl Oncol. 11:1160–1170.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schulz H, Kuhn C, Hofmann S, Mayr D,
Mahner S, Jeschke U and Schmoeckel E: Overall survival of ovarian
cancer patients is determined by expression of galectins-8 and −9.
Int J Mol Sci. 19:3232018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu H, Zou X, Lin S, Hu X and Gao J:
Effects of naringin on reversing cisplatin resistance and the
Wnt/β-catenin pathway in human ovarian cancer SKOV3/CDDP cells. J
Int Med Res. 48:3000605198878692020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zou GP, Yu CX, Shi SL, Li QG, Wang XH, Qu
XH, Yang ZJ, Yao WR, Yan DD, Jiang LP, et al: Mitochondrial
dynamics mediated by DRP1 and MFN2 contributes to cisplatin
chemoresistance in human ovarian cancer SKOV3 cells. J Cancer.
12:7358–7373. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Helland Å, Anglesio MS, George J, Cowin
PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk
N, Rustgi AK, et al: Deregulation of MYCN, LIN28B and LET7 in a
molecular subtype of aggressive high-grade serous ovarian cancers.
PLoS One. 6:e180642011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghasemi DR, Sill M, Okonechnikov K,
Korshunov A, Yip S, Schutz PW, Scheie D, Kruse A, Harter PN,
Kastelan M, et al: MYCN amplification drives an aggressive form of
spinal ependymoma. Acta Neuropathol. 138:1075–1089. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Oliveira CB, Comunello LN, Maciel ES,
Giubel SR, Bruno AN, Chiela EC, Lenz G, Gnoatto SC, Buffon A and
Gosmann G: The inhibitory effects of phenolic and terpenoid
compounds from Baccharis trimera in Siha cells: Differences in
their activity and mechanism of action. Molecules. 18:11022–11032.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Plati J, Bucur O and Khosravi-Far R:
Dysregulation of apoptotic signaling in cancer: Molecular
mechanisms and therapeutic opportunities. J Cell Biochem.
104:1124–1149. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang H, Luo Y, Qiao T, Wu Z and Huang Z:
Luteolin sensitizes the antitumor effect of cisplatin in
drug-resistant ovarian cancer via induction of apoptosis and
inhibition of cell migration and invasion. J Ovarian Res.
11:932018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Green DR and Kroemer G: The
pathophysiology of mitochondrial cell death. Science. 305:626–629.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vousden KH: p53: Death star. Cell.
103:691–694. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pistritto G, Trisciuoglio D, Ceci C,
Garufi A and D'Orazi G: Apoptosis as anticancer mechanism: Function
and dysfunction of its modulators and targeted therapeutic
strategies. Aging (Albany NY). 8:603–619. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
An SH, Kang JH, Kim DH and Lee MS: Vitamin
C increases the apoptosis via up-regulation p53 during cisplatin
treatment in human colon cancer cells. BMB Rep. 44:211–216. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li X, Mu J, Lin Y, Zhao J and Meng X:
Combination of cyanidin-3-O-glucoside and cisplatin induces
oxidative stress and apoptosis in HeLa cells by reducing activity
of endogenous antioxidants, increasing bax/bcl-2 mRNA expression
ratio, and downregulating Nrf2 expression. J Food Biochem.
45:e138062021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Righetti SC, Perego P, Corna E, Pierotti
MA and Zunino F: Emergence of p53 mutant cisplatin-resistant
ovarian carcinoma cells following drug exposure: Spontaneously
mutant selection. Cell Growth Differ. 10:473–478. 1999.PubMed/NCBI
|
|
43
|
Xie X, Lozano G and Siddik ZH:
Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor
cells promotes MDM4 recruitment and decreases stability and
transactivity of p53. Oncogene. 35:4798–806. 2016. View Article : Google Scholar : PubMed/NCBI
|
